Methods of using GLP-1 receptor agonists to treat pancreatitis
View Patent ↗The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
1. A method for treating acute pancreatitis in a human in need thereof comprising administering to the human a therapeutically effective amount of exenatide to treat acute pancreatitis.
2. A method for treating pancreatitis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist to treat pancreatitis.
3. The method of claim 2 , wherein the pancreatitis is acute pancreatitis.
4. The method of claim 3 , wherein the acute pancreatitis is acute hemorrhagic pancreatitis.
5. The method of claim 3 , wherein the acute pancreatitis is acute necrotizing pancreatitis.
6. The method of claim 3 , wherein the acute pancreatitis is acute hemorrhagic-necrotizing pancreatitis.
7. The method of claim 2 , wherein the GLP-1 receptor agonist is exenatide.
8. The method of claim 2 , wherein the GLP-1 receptor agonist is a peptide having at least 75% sequence identity to exenatide.
9. The method of claim 2 , wherein the GLP-1 receptor agonist is a peptide having at least 90% sequence identity to exenatide.
10. The method of claim 2 , wherein the GLP-1 receptor agonist is lixisenatide.
11. The method of claim 2 , wherein the GLP-1 receptor agonist is liraglutide.
12. The method of claim 2 , wherein the GLP-1 receptor agonist is dulaglutide.
13. The method of claim 2 , wherein the GLP-1 receptor agonist is albiglutide or taspoglutide.
14. The method of claim 2 , wherein the GLP-1 receptor agonist is lixisenatide; CJC-1134; SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:49; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58 or SEQ ID NO:59.
15. The method of claim 2 , wherein the GLP-1 receptor agonist is LY2428757; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; HXaa 8 EGTFTSDVSSYLEXaa 22 Xaa 23 AAKEFIXaa 30 WLXaa 33 Xaa 34 GXaa 36 Xaa 37 (SEQ ID NO: 25); wherein Xaa 8 is A, V, or G; Xaa 22 is G, K, or E; Xaa 23 is Q or K; Xaa 30 is A or E; Xaa 33 is V or K; Xaa 34 is K, N, or R; Xaa 36 is R or G; and Xaa 37 is G, H, P, or absent; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:43; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:62; or SEQ ID NO:63.
16. The method of claim 1 , wherein the acute pancreatitis is acute hemorrhagic pancreatitis.
17. The method of claim 1 , wherein the acute pancreatitis is acute necrotizing pancreatitis.
18. The method of claim 1 , wherein the acute pancreatitis is acute hemorrhagic-necrotizing pancreatitis.